Zhejiang Dongya Pharmaceutical

Zhejiang Dongya Pharmaceutical is a prominent Chinese pharmaceutical company focused on the development and large-scale manufacturing of active pharmaceutical ingredients (APIs) and chemical intermediates. Established in 1998 and headquartered in Taizhou, the company has built a robust portfolio centered on anti-infective agents, including cephalosporins, quinolones, and antifungals. Beyond its core API business, Dongya Pharmaceutical provides contract development and manufacturing organization (CDMO) services to international pharmaceutical clients. The company is publicly traded on the Shanghai Stock Exchange and adheres to global GMP standards across its production facilities. Its strategic focus remains on expanding its chemical synthesis capabilities and diversifying into therapeutic areas such as cardiovascular and metabolic health.